Table 3.
Univariate and multivariate Cox regression analyses for overall survival in patients with gastric cancer.
| Variables | Univariate analysis | Multivariate analysis | ||
|---|---|---|---|---|
| HR (95% CI) | P value | HR (95% CI) | P value | |
| Primary cohort | ||||
| Sex: male vs. female | 1.14 (0.92–1.41) | 0.223 | ||
| Age: >60 vs. ≤60 | 1.24 (0.99–1.54) | 0.053 | ||
| Tumor location | 0.001∗ | 0.057 | ||
| Middle vs. upper | 0.71 (0.54–0.93) | 0.018∗ | 0.84 (0.63–1.12) | 0.227 |
| Lower vs. upper | 0.58 (0.44–0.76) | <0.001∗ | 0.71 (0.53–0.95) | 0.020∗ |
| Grade: poorly vs. well | 0.56 (0.40–0.72) | <0.001∗ | 1.12 (0.89–1.41) | 0.350 |
| Lauren type | 0.137 | |||
| Intestinal vs. diffuse | 1.21 (0.91–1.62) | 0.195 | ||
| Mixed vs. diffuse | 0.98 (0.72–1.34) | 0.907 | ||
| Tumor size: >5 vs. ≤5 | 2.38 (1.92–2.94) | <0.001∗ | 1.19 (0.94–1.51) | 0.142 |
| Lymphovascular: yes vs. no | 1.21 (0.97–1.50) | 0.086 | ||
| Perineural: yes vs. no | 1.58 (1.29–1.93) | <0.001∗ | 1.21 (0.96–1.53) | 0.101 |
| TNM stage | <0.001∗ | <0.001∗ | ||
| II vs. I | 2.03 (1.46–2.83) | <0.001∗ | 1.77 (1.26–2.47) | 0.001∗ |
| III vs. I | 4.68 (3.46–6.34) | <0.001∗ | 3.10 (2.27–4.24) | <0.001∗ |
| Chemotherapy: Yes vs. No | 1.12 (0.91–1.37) | 0.282 | ||
| SII: >320 vs. ≤320 | 2.47 (2.01–3.04) | <0.001∗ | 1.61 (1.27–2.05) | 0.041∗ |
| NLR: >1.3 vs. ≤1.3 | 1.79 (1.47–2.20) | <0.001∗ | 1.25 (0.99–1.58) | 0.054 |
| PLR: >135 vs. ≤135 | 1.82 (1.46–2.27) | <0.001∗ | 1.04 (0.81–1.33) | 0.787 |
| MLR: >0.23 vs. ≤0.23 | 1.88 (1.54–2.31) | <0.001∗ | 1.17 (0.93–1.47) | 0.183 |
| Validation cohort | ||||
| Sex: male vs. female | 1.01 (0.62–1.63) | 0.987 | ||
| Age: >60 vs. ≤60 | 1.09 (0.88–1.36) | 0.442 | ||
| Tumor location | 0.046∗ | 0.098 | ||
| Middle vs. upper | 0.51 (0.29–0.89) | 0.018∗ | 0.61 (0.30–1.41) | 0.146 |
| Lower vs. upper | 0.51 (0.27–0.94) | 0.032∗ | 0.65 (0.38–1.10) | 0.087 |
| Grade: poorly vs. well | 1.25 (1.01–1.54) | 0.041∗ | 1.48 (0.95–2.29) | 0.080 |
| Lauren type | 0.386 | |||
| Intestinal vs. diffuse | 0.65 (0.34–1.25) | 0.196 | ||
| Mixed vs. diffuse | 0.99 (0.63–1.57) | 0.979 | ||
| Tumor size: >5 vs. ≤5 | 1.72 (1.09–2.70) | 0.019∗ | 1.81 (0.81–4.04) | 0.151 |
| Lymphovascular: yes vs. no | 1.48 (0.90–2.43) | 0.118 | ||
| Perineural: yes vs. no | 1.70 (1.06–2.72) | 0.028∗ | 1.43 (0.61–3.39) | 0.414 |
| TNM stage | <0.001∗ | <0.001∗ | ||
| II vs. I | 2.91 (1.45–5.83) | 0.003∗ | 3.19 (1.43–3.63) | 0.002∗ |
| III vs. I | 7.12 (3.50–14.50) | <0.001∗ | 7.05 (3.15–15.81) | <0.001∗ |
| Chemotherapy: yes vs. no | 1.26 (0.79–2.01) | 0.001∗ | ||
| SII: >320 vs. ≤320 | 2.75 (1.75–4.32) | <0.001∗ | 2.94 (1.83–4.73) | <0.001∗ |
| NLR: >1.3 vs. ≤1.3 | 2.03 (1.23–3.35) | 0.006∗ | 1.71 (0.96–3.39) | 0.067 |
| PLR: >135 vs. ≤135 | 1.90 (1.24–2.94) | 0.004∗ | 1.46 (0.93–2.30) | 0.102 |
| MLR: >0.23 vs. ≤0.23 | 1.56 (1.02–2.40) | 0.046∗ | 1.22 (0.76–1.95) | 0.420 |